NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) released its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analysts' expectations of $1.55 million. Kindred Biosciences had a negative net margin of 1,461.28% and a negative return on equity of 58.86%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 brokerages have issued 1 year price targets for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' share price to reach $14.44 in the next year. This suggests a possible upside of 83.4% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Press coverage about KIN stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kindred Biosciences earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 815,100 shares, a decline of 8.3% from the October 31st total of 889,100 shares. Based on an average daily volume of 113,500 shares, the days-to-cover ratio is presently 7.2 days. Approximately 2.2% of the shares of the stock are short sold. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Supernus Pharmaceuticals (SUPN), ArQule (ARQL), NextCure (NXTC), Rocket Pharmaceuticals (RCKT), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), Amneal Pharmaceuticals (AMRX), Endo International (ENDP), Rhythm Pharmaceuticals (RYTM), Opko Health (OPK), ZEALAND PHARMA/S (ZEAL), Karyopharm Therapeutics (KPTI) and Radius Health (RDUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), Cara Therapeutics (CARA), Opko Health (OPK), TherapeuticsMD (TXMD), Celgene (CELG), Corbus Pharmaceuticals (CRBP) and Global Blood Therapeutics (GBT).

Kindred Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Granahan Investment Management Inc. MA (1.90%), State Street Corp (1.65%), Silverback Asset Management LLC (1.38%), Dalton Greiner Hartman Maher & Co. (0.36%), Teton Advisors Inc. (0.09%) and Barclays PLC (0.05%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC and Barclays PLC. View Insider Buying and Selling for Kindred Biosciences.

KIN stock was bought by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Granahan Investment Management Inc. MA, Silverback Asset Management LLC, State Street Corp, Tower Research Capital LLC TRC, Metropolitan Life Insurance Co NY, Gabelli Funds LLC and Teton Advisors Inc.. View Insider Buying and Selling for Kindred Biosciences.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $7.87.

Kindred Biosciences has a market capitalization of $307.64 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]